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Abstract We tested the hypothesis that specific isoforms of
protein kinase C (PKC) are responsible for modulation of Na+
current (INa) derived from the human cardiac Na+ channel using
activators and inhibitors selective for specific PKCs. Experi-
mental results demonstrated that INa suppression was mediated
by activation of conventional PKCs (cPKCs) and possibly
resulted from channel internalization. In the presence of cPKC
inhibition, phorbol ester application unexpectedly increased Na+
current, an effect eliminated by inhibition of protein kinase A.
These findings demonstrate complex modulation of cardiac INa
by protein kinases and provide further evidence that PKC
isoforms have distinct protein targets. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Alterations in Na channel behavior that modify Na cur-
rent (INa) amplitude or channel gating can lead to the gener-
ation of life-threatening cardiac arrhythmias in humans [1,2].
Hence, the factors that regulate Na channel function are of
considerable interest from both a pathophysiologic and ther-
apeutic standpoint. As in brain and skeletal muscle, Na cur-
rent in heart can be modulated by activation of protein kinase
C (PKC), a family of kinases that modulate function and
expression of many ion channels [3,4]. At least 11 isoforms
of PKC have been identi¢ed [5] and grouped into three sub-
families based on structural considerations and requirements
for activation: conventional (c) PKCs (K, LI, LII and Q) that
require Ca2, phospholipid, and diacylglycerol or phorbol es-
ters for maximal activation; novel (n) PKCs (N, O, R, and a)
that also require phospholipid and diacylglycerol, but are in-
sensitive to Ca2 ; and atypical (a) PKCs (j and S/V), which do
not bind Ca2 or diacylglycerol, but are activated by phos-
pholipids or other mediators such as free fatty acids. Along
with this remarkable diversity, there is increasing evidence
that one or more PKC isoforms can mediate a speci¢c phys-
iological response [6].
We have previously demonstrated that Na current derived
from expression of the human cardiac Na channel, hH1, is
reduced by direct activation of PKC (using phorbol 12-myr-
istate 13-acetate, or PMA), as well as K-adrenergic receptor
stimulation, implicating a role for conventional PKCs
(cPKCs) and/or nPKCs in this e¡ect [7]. Subsequent studies
have identi¢ed expression of at least nine PKC isoforms in
human ventricular myocytes, including members of all three
subfamilies [8]. The purpose of this investigation was to test
the hypothesis that modulation of hH1 is mediated by a lim-
ited repertoire of PKCs using activators and inhibitors that
selectively target PKC isoforms or subfamilies. Our results
implicate a role for conventional isoforms, as well as potential
activation of other kinases, in the e¡ects of PKC on cardiac
Na current.
2. Materials and methods
2.1. Materials
PMA, thymeleatoxin (Tx), bisindolylmaleimide I (Bis I), and ingen-
ol 3,20-dibenzoate (IDB) were obtained from LC laboratories (Wo-
burn, MA, USA), and the protein kinase A (PKA) inhibitor 5-24 from
Calbiochem (La Jolla, CA, USA). The PKC-L inhibitor, LY379196,
was a gift from Lilly Research Laboratories (Indianapolis, IN, USA).
Peptide translocation inhibitors and activators of PKC isoforms, as
well as peptides with the same amino acid composition in a random or
‘scrambled’ order, were kindly provided by Dr. Daria Mochly-Rosen.
These peptides were synthesized at Stanford University (Stanford,
CA, USA) and characterized previously [6].
2.2. Na+ channel expression
The hH1 DNA construct (in a modi¢ed pSP64T vector [9]) was
linearized with XbaI and cRNA was transcribed using SP6 RNA
polymerase (Boehringer Mannheim, Indianapolis, IN, USA). Defolli-
culated oocytes were obtained from Xenopus laevis frogs as previously
described [10], and injected with cRNA diluted with RNase-free water
to yield Na currents 9 6 WA within 24^72 h after injection.
2.3. Electrophysiology and data analysis
Na currents were recorded using the two-electrode voltage clamp
technique and cell membrane electrical capacitance was measured as
previously described [7]. All experiments were conducted at room
temperature (22 þ 2‡C).
Analysis of data was performed using custom programs designed to
read and analyze pClamp data ¢les. The reversal potential was esti-
mated using a linear ¢t to the ascending limb of the current^voltage
relationship. A paired t test was used to compare Na current proper-
ties before and after drug/peptide administration. Comparison of nor-
malized INa density after di¡erent interventions was performed using
one-way analysis of variance (ANOVA) with the Sche¡e multiple
comparison procedure, while the time-dependent e¡ects of speci¢c
interventions were compared using ANOVA for repeated measures.
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Results are presented as mean þ S.E.M. or 95% con¢dence intervals
where indicated.
2.4. Western blot analysis of PKC isoforms in Xenopus oocytes
Cells were homogenized and subjected to immunoblotting as de-
scribed previously [8]. Yolk proteins were removed from the prepara-
tion by centrifugation at 12 000Ug for 5 min. For most experiments,
whole cell homogenate was used, with proteins separated using a 6%
sodium dodecyl sulfate^polyacrylamide gel. To investigate PKC-L
translocation, the homogenate was separated into soluble and partic-
ulate fractions by centrifugation at 100 000Ug for 30 min and the
particulate fraction used. An isoform was considered to be present
if antibodies from at least two separate commercial sources (Trans-
duction, 1:250; and Santa Cruz, dilutions reported previously [8])
recognized one or more identical bands of a size similar to that of
the positive control ( þ 5 kDa).
3. Results and discussion
3.1. Activation of cPKCs reduces hH1 current
To investigate the role of cPKC isoforms in modulating
hH1 current, we examined the e¡ects of Tx, a compound
that preferentially activates cPKC isoforms (ED50w0.1 WM
[11,12]). Bath application of Tx caused a signi¢cant reduction
in Na current at all test potentials examined (366 þ 9% at
310 mV in 40 min, Figs. 1A and 2A; n = 9). The time course
of this e¡ect was slow (Fig. 1B), with a continual decrease in
current for 40 min without saturation. Tx did not alter cell
membrane capacitance (+2 þ 10% in 40 min, Fig. 1B), indicat-
ing that measurable changes in cell membrane surface area
were not involved. Na currents were unchanged following
bath superfusion of DMSO (CTRL, Fig. 2A), eliminating
the possibility of a non-speci¢c e¡ect due to either experimen-
tal time or vehicle.
To further characterize this e¡ect, we investigated whether
Tx altered the voltage dependence of channel gating. There
was no signi¢cant change in the midpoint (V1=2) of the INa
activation or inactivation curve with Tx (Fig. 1C). Using a
two-pulse protocol [7], the time course of Na current recov-
ery from inactivation was determined. The recovery process
was best ¢t with a bi-exponential function, and Tx did not
signi¢cantly alter either the fast or slow components (dfast/
dslow = 9.1 þ 1.0/426 þ 34 ms before and 11.9 þ 1.1/429 þ 130
ms after Tx). Taken together, these results with Tx are similar
to those obtained previously with phorbol ester application
and K-adrenergic receptor stimulation [7], suggesting that
PKC modulates hH1 current by activating cPKC isoforms.
To further con¢rm this hypothesis, additional experiments
were performed using inhibitors of PKC (Fig. 2A). Pre-incu-
bation with the general PKC inhibitor Bis I (1 WM) eliminated
the reduction in Na current seen with Tx, indicating that this
e¡ect was mediated by PKC activation. Receptors for acti-
vated C kinase, or RACKs, are anchoring proteins that target
PKC isoforms to their substrates during translocation [6].
Based on the binding site of a RACK to the C2 or Ca2-
binding region of PKC-L, a synthetic peptide termed LC2-4
was developed and found to speci¢cally inhibit translocation
and activation of cPKCs [6,13]. Pre-injection of LC2-4, but
not the analogous peptide having a randomly scrambled ami-
no acid sequence (LC2-4*), completely inhibited the e¡ect of
Tx to suppress hH1 current (Fig. 2A), demonstrating that this
compound reduced hH1 currents by speci¢c activation of
Fig. 1. E¡ect of Tx on hH1 current. A: Na currents were recorded under control conditions (left) and after exposure to Tx 0.1 WM for 40
min (right). The pulse protocol is shown in the inset. B: Normalized hH1 current amplitude (at 310 mV; b) and cell membrane electrical ca-
pacitance (a) are shown as a function of time following bath application of Tx (arrow). C: Activation curves on the right (generated from
data in A) and inactivation curves on the left (generated by two second pre-pulses from 3140 to 330 mV, followed by a 310 mV test pulse)
are shown under control conditions (b) and after Tx (a). Data were normalized to peak current amplitude and the curves were ¢tted with a
Boltzmann function. For activation, V1=2 was 332 þ 1 mV before and 331 þ 1 mV after Tx; for inactivation, values were 373 þ 1 mV before
and 373 þ 0.4 mV after Tx.
FEBS 24810 20-4-01
H.-G. Shin, K.T. Murray/FEBS Letters 495 (2001) 154^158 155
cPKC isoforms. LC2-4 itself caused a small increase in hH1
current size (+9 þ 7% in 40 min, data not shown; n = 5), in-
dicating that basal cPKC activity caused tonic suppression of
Na current amplitude.
3.2. PKC-L has a minor role in the e¡ects of cPKC activation
While speci¢c inhibitors of most individual PKC isoforms
are currently not available, compounds that inhibit both
PKC-LI and PKC-LII with high speci¢city (IC50 0.03^0.05
WM vs. v0.3 WM for other PKC isoforms) have recently
been described [14]. Following pre-incubation of cells with
the PKC-L-speci¢c inhibitor LY379196, Tx still caused
marked suppression of hH1 current (reduction of INa in the
presence of LY379196 0.1 mM did not di¡er signi¢cantly
from Tx alone, Fig. 2A). Similar results were obtained follow-
ing direct injection of LY379196, while exposure of cells to
LY379196 alone had no e¡ect on hH1 current (data not
shown). Western analysis was performed to determine
whether LY379196 could inhibit activation of PKC-L in Xeno-
pus oocytes. As previously reported [15,16], immunoblotting
revealed the presence of both PKC-K and PKC-L in these cells
(as shown for PKC-L in Fig. 2B). In the presence of Tx, PKC-
L expression in the particulate fraction increased, while pre-
incubation with LY379196 reproducibly prevented this e¡ect
(n = 3), indicating that the PKC-L inhibitor could indeed in-
hibit translocation of the isoform in these cells. These data
indicate that PKC-L plays a relatively minor role in the e¡ect
of cPKCs to modulate hH1 current.
With respect to other cPKC isoforms, expression of PKC-Q
is almost exclusively limited to neuronal tissue [17,18], and we
did not detect this isoform in Xenopus oocytes (although anti-
bodies directed against mammalian PKCs may not recognize
Xenopus protein). In light of the tissue-speci¢c expression of
PKC-Q, our data with LY379196 suggest that PKC-K is
largely responsible for cPKC-mediated suppression of hH1
current.
3.3. Activation of nPKCs does not modulate hH1 current
While conventional and aPKC isoforms have been puri¢ed
or cloned from Xenopus oocytes [15,16,19], the presence of
nPKCs in these cells is also assured given the ubiquitous na-
ture of some nPKCs (e.g. PKC-N) [17], although we did not
convincingly detect any nPKC isoforms by immunoblotting
(data not shown). To determine whether nPKCs can also
modulate hH1 current, we investigated the e¡ects of IDB, a
selective activator of nPKCs (at 0.01^0.05 WM) [20,21]. IDB
(0.05 WM) had no e¡ect on hH1 currents (Fig. 3A,C),
although increasing concentrations caused a reduction in
INa. While a speci¢c inhibitor of nPKCs is currently not avail-
able, this reduction in INa was prevented by pre-injection of
the cPKC inhibitor LC2-4 (Fig. 3B,C), indicating that it likely
resulted from the non-speci¢c activation of cPKCs known to
occur at high concentrations of IDB [21].
Previous studies demonstrate that PKC-O can regulate nu-
merous cardiomyocyte properties including growth, response
to ischemic preconditioning, and contraction rate, as well as
the amplitude of cardiac L-type Ca2 current [6,22,23]. To
examine the role of PKC-O in modulating hH1 current, oo-
cytes were pre-injected with the isoform-speci¢c peptide an-
tagonist OV1-2 prior to bath application of PMA 0.01 WM (at
higher concentrations of PMA, the e⁄cacy of the peptide
inhibitor is reduced; Daria Mochly-Rosen, personal commu-
nication). Although the PKC-O inhibitor blunted the e¡ect of
PMA to reduce INa (Fig. 3C), this also occurred in cells in-
jected with the scrambled inhibitor (OV1-2*), indicating that it
resulted from a non-speci¢c e¡ect of peptide injection. More-
over, injection of cells with the speci¢c PKC-O agonist iO-
RACK did not suppress Na current (Fig. 3C). These results
do not support a role for PKC-O, or other nPKCs, in the
modulation of hH1 current.
3.4. PMA increases hH1 current by cross-activation of PKA
Because PMA can activate both conventional and nPKC
isoforms, we examined the e¡ects of cPKC inhibition on mod-
ulation of hH1 current by PMA. Pre-injection of LC2-4 not
only inhibited the PMA-induced reduction in INa, but also
unmasked a transient increase in hH1 current by PMA (Fig.
4A). This ¢nding resembled the transient initial increase in INa
that we observed at low concentrations of Tx (+5 þ 2% in 25
min at 50 nM; n = 8) and PMA (+12 þ 4% in 25 min at 1 nM;
n = 4). Previous work by us and others has shown that hH1
current is increased by activation of PKA [10,24]. In addition,
it is well established that in some circumstances, stimulation
of PKC can modulate the activity of PKA by multiple di¡er-
ent mechanisms [25]. To test the hypothesis that the transient
increase in INa was due to cross-activation of PKA, cells were
injected with the peptide inhibitor of PKA 5-24 (PKI), as well
as LC2-4. Pre-injection of PKI eliminated the e¡ect of PMA
to increase hH1 current in the presence of LC2-4 (Fig. 4A),
Fig. 2. E¡ect of PKC inhibitors. A: Bar graphs ( þ 95% con¢dence
intervals; n = 5^9 each; *P9 0.05 compared to CTRL) display nor-
malized INa density after a 40 min exposure to DMSO 0.01%
(CTRL) or Tx (0.1 WM), and following a 40 min exposure to Tx
after pre-incubation (20 min) or pre-injection (30 min) with either
Bis I (1 WM); LC2-4 (¢nal intracellular concentration 0.05, 0.1, or
50 WM); the scrambled peptide LC2-4* (50 WM); and LY379196
(0.05 or 0.1 WM). B: Rat brain (RB, positive control, lane 1), and
the particulate fraction of oocytes exposed for 1 h to bath solution
(lane 2), Tx (0.1 WM, lane 3), and pre-incubation (1 h) with
LY379196 (0.1 WM) followed by Tx (lane 4), were subjected to
Western analysis using an antibody to PKC-L (Santa Cruz, 1:1000).
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indicating that the enhancement of current was likely medi-
ated by cross-activation of PKA.
The mechanism of PKA activation in these experiments
remains uncertain. Phorbol esters themselves can activate
PKA, as recently described for modulation of K current
derived from the human ether-a-go-go-related gene product
(hERG) [26]. In addition, physiologic activation of PKC can
alter cAMP generation, with either increased or decreased
Fig. 4. Cross-activation of PKA and e¡ects of ConA. A: The time course of normalized INa density is shown in oocytes pre-injected with the
cPKC inhibitor LC2-4 alone (3PKI, b, ¢nal intracellular concentration 50 WM) or LC2-4 plus the PKA inhibitor (+PKI, a, ¢nal intracellular
concentration of PKI 10 WM), followed by application of PMA 0.01 WM. B: Bar graphs ( þ 95% con¢dence intervals; n = 4^6 each; *P9 0.05
compared to CTRL) illustrate normalized INa density after a 40 min exposure to increasing concentrations (0.1, 0.3 mg/ml) of ConA, and to
Tx (0.1 WM) or PMA (0.01 WM) after pre-incubation (30 min) with ConA (0.1 mg/ml).
Fig. 3. Lack of e¡ect of nPKC isoforms on hH1 current. A: Normalized INa density (at 310 mV) is shown over time following exposure to
0.05 WM (b), 0.5 WM (S) and 1 WM (F) IDB (n = 6 each). B: In cells pre-injected with the cPKC inhibitor LC2-4, normalized INa density is
shown following exposure to IDB (1 WM, a ; n = 6). Data obtained with IDB 1 WM in the absence of LC2-4 pre-injection (F ; also shown in A)
are aligned for comparative purposes. C: Bar graphs ( þ 95% con¢dence intervals; n = 5^9 each; *P90.05 compared to CTRL in Fig. 2A) of
normalized INa density are shown after a 40 min exposure to: increasing concentrations (0.05, 0.5, 1.0 WM) of IDB; IDB (1 WM) after pre-in-
jection (30 min) of LC2-4; PMA (0.01 WM); PMA (0.01 WM) after pre-injection (30 min) of OV1-2 (0.1 WM) or the scrambled peptide OV1-2*
(0.1 WM); and injection of iORACK (0.1 WM).
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production, to modulate PKA activity [25]. Thus, PMA could
cause cross-activation of PKA either directly, or by activating
a nPKC not stimulated by IDB. Previous studies have shown
that the e¡ects of PKC activation on cardiac Na current
derived from native myocytes and recombinant channels
have been controversial, with both an increase and decrease
reported [3,4,10,27,28]. In one study with ventricular myo-
cytes, low concentrations of angiotensin II increased cardiac
INa while high concentrations suppressed it [29], analogous to
our results with Tx and PMA. Given our ¢ndings, a plausible
explanation for this phenomenon is di¡erential activation of
PKA and PKC at di¡erent concentrations of agonist.
3.5. Concanavalin A (ConA) inhibits suppression of hH1
current
We have recently shown that the increase in hH1 current
with PKA stimulation results from modulation of channel
tra⁄cking to increase the number of channels in the plasma
membrane [10]. The slow, non-saturable reduction in INa that
occurred with Tx (Fig. 1B) and PMA [7] suggested a similar
mechanism. To begin to test the hypothesis that channel traf-
¢cking is involved in the e¡ect of PKC activation, cells were
initially exposed to ConA, a lectin that cross-links extracellu-
lar carbohydrate moieties and prevents internalization of
membrane proteins [30]. Bath application of ConA caused a
slow, concentration-dependent increase in Na current (Fig.
4B), an expected e¡ect if channel internalization was inhib-
ited. Moreover, pre-incubation with ConA totally prevented
suppression of hH1 current by either Tx or PMA (Fig. 4B).
These results suggest that activation of PKC reduced cardiac
Na current by promoting channel internalization, rather
than a direct e¡ect to modulate channel function. It is unlikely
that this reduction in INa results from non-speci¢c internal-
ization of oocyte plasma membrane, given that: (1) cell mem-
brane electrical capacitance was unchanged despite a signi¢-
cant reduction in INa ; and (2) internalization of a large
portion of oocyte membrane would have been required, while
cells were unchanged microscopically.
Because ConA can cause other e¡ects besides inhibition of
membrane protein internalization [31], additional experiments
are required to con¢rm the role of channel internalization in
the e¡ects of PKC activation. However, given the increasing
recognition that the tra⁄cking of membrane proteins into and
out of the plasma membrane can be regulated by protein ki-
nase activation, as for GLUT4 glucose transporters and the
cystic ¢brosis transmembrane conductance regulator CFTR
[32], it is likely that ion channels are subjected to similar
regulation. For example as noted above, we have shown
that PKA activation increases tra⁄cking of hH1 into the
plasma membrane [10]. In addition in immature neurons, per-
sistent activation of Na channels can promote channel inter-
nalization [33].
In summary, our results demonstrate additional evidence
that a speci¢c physiological response can be mediated by a
restricted number of PKC isoforms due to compartmentaliza-
tion, or co-localization of substrate and enzyme at restricted
locations within the cell. In addition, the potential to modify
channel tra⁄cking as well as function, and for agonist-medi-
ated cross-activation of other kinases, illustrates that PKC
modulation of cardiac Na current is likely a complex pro-
cess.
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